The DOI matches its Crossref record.
Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon
Abstract
Several recent reports have suggested that foetal ventral mesencephalic transplants could alleviate motor symptoms in patients with Parkinson's disease. Expectations of future success must be clarified by precise analysis of the extent and limitation of recovery associated with an assessment of function of the graft using [18F]fluorodopa (18F-dopa) PET. Two patients with idiopathic Parkinson's disease, severely impaired despite optimal medication, have been followed 10 and 17 months after stereotaxic unilateral intrastriatal transplantation of neural cells dissociated from human foetal ventral mesencephalon. Analysis of the clinical evolution complied with the protocol established in the 'Core Assessment Program for Intracerebral Transplantation'. Both patients have benefited from the transplantation in their daily activities and in motor timed tests, although they still exhibit parkinsonian symptoms and require L-dopa therapy. This is associated with a gradual increase in 18F-dopa uptake at the site of grafting. There are two major clinical changes: (i) a bilateral motor improvement for the speed of movements (the quality of movements improved almost exclusively on the side contralateral to the graft); (ii) a change in the outcome of the L-dopa treatment as exemplified by a postoperative transient period of heavy dyskinesias and subsequent additive actions of the two treatments. These results confirm that neural transplantation may be useful for patients with Parkinson's disease. The improvement recorded on the side ipsilateral to the graft does not match that observed on the contralateral side and it is proposed that bilateral transplantation may be necessary. The existence of a transient postoperative period of heavy dyskinesias suggests that the patients may benefit from a controlled decrease of L-dopa intake after grafting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Self-citationKordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J. G., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Smith, D. A., Nauert, G. M., Perl, D. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321702 · Cited by 860
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Mendez, I., Sanchez-Pernaute, R., Cooper, O., Viñuela, A., Ferrari, D., Björklund, L., Dagher, A., & Isacson, O. (2005) · Brain · doi:10.1093/brain/awh510 · Cited by 438
Fetal nigral transplantation as a therapy for Parkinson's disease
Olanow, C. W., Kordower, J. H., & Freeman, T. B. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80038-5 · Cited by 416
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease
Freeman, T. B., Olanow, C. W., Hauser, R. A., Nauert, G. M., Smith, D. A., Borlongan, C. V., Sanberg, P. R., Holt, D. A., Kordower, J. H., Vingerhoets, F. J. G., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380307 · Cited by 403
Wenning, G. K., Odin, P., Morrish, P., Rehncrona, S., Widner, H., Brundin, P., Rothwell, J. C., Brown, R., Gustavii, B., Hagell, P., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420115 · Cited by 369
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
Barker, R. A., Barrett, J., Mason, S. L., & Björklund, A. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70295-8 · Cited by 365
Long-term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Hauser, R. A., Freeman, T. B., Snow, B. J., Nauert, M., Gauger, L., Kordower, J. H., & Olanow, C. W. (1999) · Archives of Neurology · doi:10.1001/archneur.56.2.179 · Cited by 353
Cell therapy in Parkinson’s disease
Lindvall, O., & Björklund, A. (2004) · NeuroRX · doi:10.1602/neurorx.1.4.382 · Cited by 346
Kordower, J. H., Rosenstein, J. M., Collier, T. J., Burke, M. A., Chen, E.-Y., Li, J. M., Martel, L., Levey, A. E., Mufson, E. J., Freeman, T. B., et al. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960624)370:2<203::aid-cne6>3.0.co;2-6 · Cited by 313
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 306
The future of stem cell therapies for Parkinson disease
Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 306
Brundin, P. (2000) · Brain · doi:10.1093/brain/123.7.1380 · Cited by 305
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease
Kordower, J. H., Freeman, T. B., Chen, E., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Snow, B., & Warren Olanow, C. (1998) · Movement Disorders · doi:10.1002/mds.870130303 · Cited by 298
McRae, C., Cherin, E., Yamazaki, T. G., Diem, G., Vo, A. H., Russell, D., Ellgring, J. H., Fahn, S., Greene, P., Dillon, S., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.4.412 · Cited by 278
Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft
Hagell, P. (1999) · Brain · doi:10.1093/brain/122.6.1121 · Cited by 274
Piccini, P., Lindvall, O., Bj�rklund, A., Brundin, P., Hagell, P., Ceravolo, R., Oertel, W., Quinn, N., Samuel, M., Rehncrona, S., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<689::aid-ana1>3.0.co;2-n · Cited by 255
Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
Tabar, V., Sarva, H., Lozano, A. M., Fasano, A., Kalia, S. K., Yu, K. K. H., Brennan, C., Ma, Y., Peng, S., Eidelberg, D., et al. (2025) · Nature · doi:10.1038/s41586-025-08845-y · Cited by 181
Metadata
- Authors
- Peschanski, M., Defer, G., N'Guyen, J. P., Ricolfi, F., Monfort, J. C., Remy, P., Geny, C., Samson, Y., Hantraye, P., Jeny, R., Gaston, A., Kéravel, Y., Degos, J. D., & Cesaro, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1994
- Volume
- 117
- Issue
- 3
- Pages
- 487-499
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2116246431
- Cited by
- 280
- References
- 0
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.